Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Obstet Gynecol. 2009 Apr;200(4):422.e1-9. doi: 10.1016/j.ajog.2008.11.031. Epub 2009 Jan 24.

Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review.

Author information

  • 1Oregon Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR, USA.

Abstract

OBJECTIVE:

We conducted a systematic review to evaluate the characteristics of human papillomavirus testing, particularly Hybrid Capture 2, in follow-up evaluations after treatment for cervical intraepithelial neoplasia for the detection of residual or recurrent cervical intraepithelial neoplasia grade >/= 2.

STUDY DESIGN:

Medline was searched for relevant studies that were published between 1992 and September 2007. Of the 1107 citations that were identified, 20 articles met the inclusion criteria.

RESULTS:

Studies that used polymerase chain reaction testing were too heterogeneous to combine. We identified 5 studies that performed both Hybrid Capture 2 and colposcopy. Pooled sensitivity for Hybrid Capture 2 was 90.7% (95% CI, 75.4-96.9%), and pooled specificity was 74.6% (95% CI, 60.4-85.0%). Pooled sensitivity for cervical cytologic testing was 76.6% (95% CI, 62.0-86.8%), and pooled specificity was 89.7% (95% CI, 22.7-99.6%).

CONCLUSION:

Hybrid Capture 2 testing can identify approximately 91% of women with residual or recurrent cervical intraepithelial neoplasia grade >/= 2; however, approximately 30% of women would undergo colposcopy in follow-up evaluation.

PMID:
19167697
PMCID:
PMC2784953
DOI:
10.1016/j.ajog.2008.11.031
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central Icon for PubMed Health
    Loading ...
    Support Center